See more : NH Investment & Securities Co., Ltd. (005945.KS) Income Statement Analysis – Financial Results
Complete financial analysis of Outlook Therapeutics, Inc. (OTLK) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of Outlook Therapeutics, Inc., a leading company in the Biotechnology industry within the Healthcare sector.
You may be interested
- Xingda International Holdings Limited (XNGIF) Income Statement Analysis – Financial Results
- Sena Development Public Company Limited (SENA.BK) Income Statement Analysis – Financial Results
- Asante Incorporated (6073.T) Income Statement Analysis – Financial Results
- Siam Technic Concrete Public Company Limited (STECH.BK) Income Statement Analysis – Financial Results
- BayCom Corp (BCML) Income Statement Analysis – Financial Results
Outlook Therapeutics, Inc. (OTLK)
About Outlook Therapeutics, Inc.
Outlook Therapeutics, Inc., a late clinical-stage biopharmaceutical company, focuses on developing and commercializing monoclonal antibodies for various ophthalmic indications. Its lead product candidate is ONS-5010, an ophthalmic formulation of bevacizumab product candidate that is in Phase-III clinical trial for the treatment of wet age-related macular degeneration and other retina diseases. Outlook Therapeutics, Inc. has collaboration and license agreements with IPCA Laboratories Limited; Laboratorios Liomont, S.A. de C.V.; BioLexis Pte. Ltd.; and Zhejiang Huahai Pharmaceutical Co., Ltd. The company was formerly known as Oncobiologics, Inc. and changed its name to Outlook Therapeutics, Inc. in November 2018. Outlook Therapeutics, Inc. was incorporated in 2010 and is based in Iselin, New Jersey.
| Metric | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 8.15M | 3.09M | 3.81M | 2.98M | 5.22M | 9.05M |
| Cost of Revenue | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 23.81K | 18.50K | 23.81K | 32.76K | 38.88K | 14.12K |
| Gross Profit | 0.00 | -44.19K | -204.69K | -262.14K | -554.07K | 8.12M | 3.07M | 3.79M | 2.95M | 5.18M | 9.04M |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 99.71% | 99.40% | 99.38% | 98.90% | 99.26% | 99.84% |
| Research & Development | 41,763.05B | 26.45M | 42.33M | 38.96M | 26.34M | 23.81M | 18.50M | 23.81M | 32.76M | 38.88M | 14.12M |
| General & Administrative | 29,940.19B | 26.67M | 20.74M | 12.77M | 9.97M | 9.37M | 14.23M | 15.88M | 21.64M | 12.91M | 7.32M |
| Selling & Marketing | 0.00 | 0.00 | 0.00 | 279.68K | -1.90M | -3.85M | -7.25M | -2.69M | -2.47M | 0.00 | 0.00 |
| SG&A | 29,940.19B | 26.67M | 20.74M | 13.05M | 8.08M | 5.52M | 6.97M | 13.19M | 19.17M | 12.91M | 7.32M |
| Other Expenses | 0.00 | 0.00 | -882.90K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 71,703.24B | 53.13M | 63.07M | 51.73M | 36.31M | 29.33M | 25.48M | 39.69M | 51.93M | 51.78M | 21.44M |
| Cost & Expenses | 0.00 | 53.13M | 63.07M | 51.73M | 36.31M | 32.69M | 28.53M | 39.69M | 54.74M | 51.78M | 21.44M |
| Interest Income | -906.15B | 1.56K | 1.49K | 936.13 | 1.76K | 3.47K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 3,156.96B | 1.56M | 1.49M | 936.00K | 1.76M | 3.47M | 3.89M | 5.63M | 1.47M | 2.30M | 901.05K |
| Depreciation & Amortization | 0.00 | 44.19K | 204.69K | 262.14K | 554.07K | 3.36M | 3.05M | 2.69M | 2.39M | 1.82M | 878.48K |
| EBITDA | -71,703.24B | -57.38M | -62.87M | -51.46M | -35.76M | -31.11M | -26.79M | -30.03M | -48.95M | -44.74M | -11.51M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -265.98% | -725.17% | -870.73% | -1,656.75% | -857.18% | -127.22% |
| Operating Income | -71,703.24B | -53.13M | -63.07M | -51.73M | -36.84M | -36.30M | -25.44M | -35.88M | -51.76M | -46.56M | -12.39M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -445.60% | -824.09% | -941.36% | -1,737.10% | -892.13% | -136.92% |
| Total Other Income/Expenses | -3,660.68B | -5.85M | -2.98M | -1.43M | -1.67M | -1.64M | -4.10M | -2.47M | -1.85M | -2.30M | -901.05K |
| Income Before Tax | -75,363.91B | -58.98M | -66.05M | -53.16M | -38.51M | -37.93M | -33.74M | -38.35M | -53.23M | -48.86M | -13.29M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -465.68% | -1,092.78% | -1,006.10% | -1,786.37% | -936.15% | -146.88% |
| Income Tax Expense | 2.80B | 2.80K | 2.80K | 2.00K | -3.27M | -3.41M | -3.65M | 501.50K | 103.00K | -190.11K | 439.02K |
| Net Income | -75,366.71B | -58.98M | -66.05M | -53.16M | -35.24M | -34.52M | -46.11M | -38.85M | -53.33M | -47.39M | -13.73M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | -423.81% | -1,493.57% | -1,019.26% | -1,789.83% | -908.05% | -151.73% |
| EPS | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.75 | -495.71 | -504.47 | -155.35 |
| EPS Diluted | -4.06K | -4.72 | -6.23 | -6.96 | -9.71 | -37.96 | -50.70 | -258.54 | -495.71 | -504.47 | -155.35 |
| Weighted Avg Shares Out | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.14K | 107.58K | 93.95K | 88.40K |
| Weighted Avg Shares Out (Dil) | 18.55B | 12.51M | 10.60M | 7.63M | 3.63M | 909.59K | 909.59K | 150.26K | 107.58K | 93.95K | 88.40K |
Outlook Therapeutics® Announces NICE Recommendation of LYTENAVA™ (bevacizumab gamma) for the Treatment of Wet AMD
First positive reimbursement decision worldwide for LYTENAVA™; First launch anticipated in H1 2025 LYTENAVA™ is the first and only approved ophthalmic formulation of bevacizumab for the treatment of wet AMD in the European Union (EU) and United Kingdom (UK) 40,000...
Outlook Therapeutics® Announces Executive Leadership Transition
ISELIN, N.J., Dec. 03, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for LYTENAVA™ (bevacizumab gamma), the first ophthalmic formulation of...
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Outlook Therapeutics, Inc. - OTLK
NEW YORK , Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Outlook Therapeutics, Inc. ("Outlook" or the "Company") (NASDAQ: OTLK). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext.
OTLK Stock Falls on Failure to Meet Non-Inferiority Goal in AMD Study
Outlook Therapeutics stock tanks 65% as ONS-5010 fails to meet the pre-specified non-inferiority endpoint at week 8 in the 90-day NORSE EIGHT study for wet AMD.
Why Is Eye Disease-Focused Outlook Therapeutics Stock Trading Lower On Wednesday?
Outlook Therapeutics Inc. OTLK revealed preliminary topline results of NORSE EIGHT, the second of two clinical trials evaluating ONS-5010 in wet AMD patients.
Outlook Therapeutics® Announces Preliminary Topline Results of NORSE EIGHT Clinical Trial
ISELIN, N.J., Nov. 27, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation...
Outlook Therapeutics® to Present at the Guggenheim Healthcare Innovation Conference
Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET Live fireside chat with CEO, Russ Trenary, on November 12th at 2:30 PM ET
OUTLOOK ALERT: Bragar Eagel & Squire, P.C. is Investigating Outlook Therapeutics, Inc. on Behalf of Long-Term Stockholders and Encourages Investors to Contact the Firm
NEW YORK, Oct. 11, 2024 (GLOBE NEWSWIRE) -- Bragar Eagel & Squire, P.C., a nationally recognized shareholder rights law firm, is investigating potential claims against Outlook Therapeutics, Inc. (NASDAQ: OTLK) on behalf of long-term stockholders following a class action complaint...
Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET
Outlook Therapeutics® Participates in the 2nd Annual Chardan Virtual Ophthalmology Conference Series
Webcast replay of fireside chat now available
Source: https://incomestatements.info
Category: Stock Reports